AKTS
Aktis Oncology, Inc.
18.00$
+0.8%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q3 24 | Q4 24 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 45.6% | 43.3% | 40.2% | 30.3% | 23.3% | 27.8% | 93.6% | 92.2% | 89.4% | 86.9% | 94.3% | 94.1% | |
| 35.2% | 33.5% | 28.9% | 20.3% | 11.5% | 14.8% | 66.6% | 11.4% | 64.6% | 14.3% | 64.4% | 14.8% | |
| 35.2% | 33.5% | 28.9% | 20.3% | 11.5% | 14.8% | 92.7% | 91.1% | 88.2% | 85.6% | 93.4% | 92.8% | |
| 2.4% | 2.7% | 3.2% | 3.1% | 5.4% | 5.4% | 2.1% | – | – | – | 0.4% | 0.4% | |
| 4.4% | 4.8% | 5.1% | 4.9% | 4.9% | 5.0% | 0.9% | – | – | – | – | – | |
| 6.1% | 9.2% | 9.8% | 11.5% | 13.0% | 6.3% | 1.9% | – | – | – | – | – | |
| 6.3% | 10.1% | 10.2% | 11.4% | 12.4% | 12.9% | 3.5% | – | – | – | – | – | |
| 40.2% | 36.2% | 42.1% | 46.7% | 51.9% | 59.2% | 122.8% | 126.9% | 147.4% | 155.2% | 12.3% | 13.0% | |
| 6.6% | 7.5% | 11.8% | 12.5% | 12.8% | 17.8% | 5.0% | 5.8% | 9.6% | 11.8% | 4.8% | 5.8% | |
| 0.4% | 0.5% | 0.6% | 0.7% | 0.9% | 2.1% | 0.4% | 0.4% | 0.5% | 0.5% | 0.2% | 0.3% | |
| 2.0% | 2.0% | 2.7% | 4.7% | 2.8% | 4.7% | 0.2% | 0.6% | 0.8% | 0.7% | 0.2% | 0.5% | |
| 59.8% | 63.8% | 57.9% | 53.3% | 48.1% | 40.8% | -22.8% | -26.9% | -47.4% | -55.2% | 87.7% | 87.0% | |
| -179.2% | -160.4% | -181.5% | -228.6% | -273.9% | -321.4% | -24.0% | -28.5% | -50.7% | -59.1% | -30.3% | -35.7% | |
| 43.5% | 43.3% | 48.2% | 56.9% | 65.3% | 89.0% | 45.8% | 16.1% | 18.8% | 20.2% | 9.6% | 9.9% |
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.